Aired Last month 2:21
american society hematology Discussed on Bloomberg Radio New York
Bloomberg Radio New York
From the news
Aired 3 years ago 46:13
Episode 16: Controversies In Hematology
This episode was recorded at the 2016 annual meeting of the American Society of Hematology (ASH) in San Diego. Youâ€™ll hear excerpts from interviews with leading experts, who discuss some of the latest clinical data and controversies in liquid cancers and blood disorders. Dr Alexis Thompson (Northwestern University), who will be President of ASH in 2018, talks about some of the latest data in Sickle Cell Disease (SCD), as well as how gene therapy and gene editing may provide a cure in the future. Dr Bruce Cheson (Georgetown) shares his perspective on what was exciting for the treatment of Chronic Lymphocytic Leukemia (CLL), and where the field is going. Dr Brian Druker (Oregon Health Sciences University) is one of the lead investigators for the Beat AML Master trial, sponsored by the Leukemia Lymphoma Society. Weâ€™ll hear what makes the adaptive study design they are employing a potential game changer for older people with acute myeloid leukemia. Dr John Leonard (Weill Cornell) offers his top 10 list of lymphoma abstracts at ASH16. Done in the style of David Letterman, weâ€™ll hear what caught his attention - and more importantly - why he selected them. Dr Michael Wenger (Genentech) talks about a novel antibody drug conjugate (ADC), polatuzumab vedotin, in development for the treatment of advanced lymphomas. You can listen to all the prior episodes and find more information on http://noveltargets.com. Copyright Â© Blue Ice Publishing LLC, 2017. All Rights Reserved.
Aired 2 years ago 44:53
Episode 21: Playing With Fire
In this episode we're exploring some controversial issues in cancer research including real world versus clinical trial experience and immune related toxicities, as well as highlighting strength and weaknesses around some encouraging new data with several therapies in development for different hematologic malignancies. Not everything about cancer immunotherapies is positive -- there are challenges associated with this promising approach too. Despite what many people may believe, it's not just about merely tweaking one's immune system and the cancer goes away. Most of the interviews you'll hear were recorded at the 2017 annual meeting of the American Society of Hematology (ASH) in Atlanta. In this episode you'll hear leading experts, including Drs Paul Richardson and Philippe Armande (Dana-Farber), Dr John Leonard (Weill Cornell), Dr Ian Flinn (Sarah Cannon), Dr Nancy Simonian (Syros) and Drs Michael Wenger and Deepak Sampath (Genentech). Some of the topics covered include: * Real world experiences in myeloma and lymphoma * The challenges of combining immune checkpoint blockade with IMiDs * How combining several immunotherapies after allo transplant can be challenging in Hodgkins Lymphoma * A look at progress with two antibody drug conjugates and physician reactions to the data * Emerging targeted therapies combinations and their outlook * Can a BCL-2 inhibitor be safely combined with other approaches in CLL * Perspectives on CAR T cell therapy and their potential competitors In particular, Dr Paul Richardson discusses real world data, tolerability, managing toxicities and some new agents on the horizon that he is excited about. We also hear from Dr John Leonard on his perspectives around several new developments in aggressive lymphomas, including brentuximab vedotin in the ECHELON-1 study and his latest thoughts around CAR T cell therapies in diffuse large cell lymphoma (DLBCL). All in all, there's much to reflect on and think about in the blood cancers and plenty to watch out for in 2018. You can find more information on the Novel Targets website (https://noveltargets.com) along with links to some of the scientific papers mentioned. Copyright Â© Blue Ice Publishing LLC, 2018. All Rights Reserved.
Aired 6 months ago 41:56
13. Nurses take charge: How to advocate for a safer working environment for staff and patients with Lorena Segovia and Linda Abramovitz
SIOP PODC Nursing Working Group: The Advocacy Toolkit Today on the podcast, we discuss a new advocacy toolkit that nurses can use to help improve the safety of their work environment and the quality of care they provide to patients. This discussion is a follow-up to episode 11, where we discussed the Baseline Nursing Standards [â€¦]